---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-036310"
form_type: "8-K"
ticker: "CNTN"
cik: "0001861657"
company_name: "Canton Strategic Holdings, Inc."
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:42:49.012894+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tharimmune licenses oral infliximab from Intract Pharma for global development

## Summary
- Exclusive global license (ex-South Korea) to INT-023/TH023, an oral anti-TNF-α monoclonal antibody infliximab.
- Intract received upfront payment, eligible for equity-linked payments, milestones, and mid-single-digit royalties on net sales.
- Tharimmune holds right of first refusal to continue development after Phase 2 trial.
- Option to license Intract's Soteria/Phloral platform for up to four additional targets.
- Oral formulation aims to replace IV infliximab (Remicade) for autoimmune diseases; multibillion-dollar market opportunity cited.

## SEC filing metadata
- accession: 0001493152-24-036310
- form_type: 8-K
- ticker: CNTN
- cik: 0001861657
- company_name: Canton Strategic Holdings, Inc.
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861657/000149315224036310/0001493152-24-036310-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861657/000149315224036310/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-036310
- JSON: https://secwatch.observer/filing/0001493152-24-036310.json
- Plain text: https://secwatch.observer/filing/0001493152-24-036310.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.